Abstract Number: 0309 • ACR Convergence 2024
Characteristics and Factors Associated with Treatment Response Among Patients with Eosinophilic Fasciitis: A Systematic Review and Meta-analysis
Background/Purpose: To date, data on the clinical features, diagnosis and the treatment of Eosinophilic Fasciitis (EF) patients are mostly derived from individual case reports, with…Abstract Number: 0636 • ACR Convergence 2024
Evaluation of Clinical, Histological and Biomarker Response After Induction Treatment of Lupus Nephritis (LN)
Background/Purpose: LN occurrs in 50 to 75 percent of SLE patients and is associated with a significant morbimortality. LN presents distinct severity, with frequent flares…Abstract Number: 1162 • ACR Convergence 2024
Evaluating the Efficacy of Rituximab in the Treatment of Refractory Adult Idiopathic Inflammatory Myositis Using Total Improvement Score: Data from a Real-World Multi-Centre Registry in the United Kingdom
Background/Purpose: B cell depletion in the form of rituximab (RTX) is an established treatment modality for idiopathic inflammatory myopathies (IIM). Treatment response is now assessed…Abstract Number: 1341 • ACR Convergence 2024
Evaluation of Width Range Index (WRI) and Neutrophil-to-Lymphocyte Ratio (NLR) in Assessing Disease Activity in Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory condition characterized by joint inflammation and systemic involvement. In this preliminary study, we explore the potential link…Abstract Number: 0520 • ACR Convergence 2023
How Do Early Disease Activity and Early Clinical Response Associate with Long-Term Outcomes with Ixekizumab in Radiographic Axial Spondyloarthritis?
Background/Purpose: The ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) advise that a patient be assessed for biological disease-modifying anti-rheumatic drug (bDMARD) treatment response…Abstract Number: 0746 • ACR Convergence 2023
The Association Between Sonographic Imaging Phenotype and Response to Treatment in Patients with Psoriatic Arthritis
Background/Purpose: Ultrasound (US) may improve characterization of psoriatic arthritis (PsA) phenotypes and help predict disease outcomes. We aimed to assess whether US phenotypes are associated…Abstract Number: 0840 • ACR Convergence 2023
Head-to-Head Comparison of TLL-018 and Tofacitinib in Patients with Active Rheumatoid Arthritis: Final Results from a Phase IIa Study
Background/Purpose: None of the currently approved treatments for rheumatoid arthritis (RA) can achieve ACR50 in >50% of the patients, and 5 – 20% of the…Abstract Number: 0974 • ACR Convergence 2023
Validation of Boolean 2.0 Criteria for Assessing Remission and Predicting Quality of Life in Korean Patients with Rheumatoid Arthritis Undergoing Targeted Therapy
Background/Purpose: The management of rheumatoid arthritis (RA) focuses on achieving remission as a treatment goal. The updated ACR/EULAR remission definition (Boolean criteria 2.0) has raised…Abstract Number: 1172 • ACR Convergence 2023
Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse
Background/Purpose: Our aim was to explore whether maintenance of remission in patients with idiopathic inflammatory myopathy (IIM) depends on glucocorticoids (GCs) after achieving remission. Therefor…Abstract Number: 1423 • ACR Convergence 2023
Impact of Upadacitinib on Enthesitis and Dactylitis by Location in Patients with Psoriatic Arthritis and an Inadequate Response to Biologic DMARDs from the SELECT-PsA 2 Trial
Background/Purpose: Enthesitis and dactylitis are associated with reduced quality of life and greater impairment in daily activities. In the SELECT-PsA 2 phase 3 trial, the…Abstract Number: 2143 • ACR Convergence 2023
Efficacy of Filgotinib in Patients with Rheumatoid Arthritis: Week 156 Results from a Long-term Extension Study
Background/Purpose: In the treatment of RA, JAK inhibitors are a valuable option to meet remission or low disease activity (LDA) treatment targets following an inadequate…Abstract Number: 2334 • ACR Convergence 2023
Remission Attainment in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period
Background/Purpose: In patients with SLE, remission is an established therapeutic goal associated with reduced damage accrual and flares, and improved health-related quality of life.1 Here,…Abstract Number: 2486 • ACR Convergence 2023
Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG a And/or Two BILAG B Scores?
Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One…Abstract Number: 2551 • ACR Convergence 2023
Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis
Background/Purpose: A key treatment goal in SLE management is the attainment of remission or LDA,1 for which various definitions exist, including “Definitions of Remission in…Abstract Number: 0459 • ACR Convergence 2023
Upadacitinib Monotherapy versus Methotrexate in Patients with Rheumatoid Arthritis: Efficacy and Safety Through 5 Years in the SELECT-EARLY Randomized Controlled Trial
Background/Purpose: To evaluate the efficacy and safety of upadacitinib (UPA) monotherapy vs MTX monotherapy over 5 yrs among MTX-naïve patients with moderately to severely active…
ACR Meeting Abstracts